Janet Hummer, MD
Ophthalmology · Indianapolis, INNPI 1336180181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,125 of the $95,621 with a category attached, or 84.8%. Regeneron Healthcare Solutions, Inc. accounts for 90.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $32,337 and has fallen 59.1% since, to $13,218 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $654.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$86K
- Novartis$7K
- Lensar, Inc.$2K
- Genentech USA, Inc.$161
- Dompe US, Inc.$157
- Cardinal Health 110 LLC$150
- plus $388 from 10 others
What the payments were for
- Consulting fees$4,2504%
- Speaking & faculty fees$81,12585%
- Travel & lodging$5,4526%
- Food & beverage$4,7495%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 90 | $86,380 |
| Novartis | 15 | $6,858 |
| Lensar, Inc. | 12 | $1,527 |
| Genentech USA, Inc. | 6 | $161 |
| Dompe US, Inc. | 3 | $157 |
| Cardinal Health 110 LLC | 1 | $150 |
| AbbVie(2 entities) | 6 | $143 |
| Bausch & Lomb Americas Inc. | 2 | $44 |
| Tarsus Pharmaceuticals, Inc. | 2 | $39 |
| Alcon | 2 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $33 |
| Glaukos Corporation | 1 | $24 |
| Thea Pharma Inc. | 1 | $21 |
| Rxsight Inc | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$54,396
- EYLEA HD$31,483
- BEOVU$2,270
- LENSAR LASER SYSTEM$1,447
- Oxervate$124
How this compares
$95,621 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 49 | $21,100 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $10,862 |
| RestasisCyclosporine | 11 | $10,019 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 37 | $8,486 |
| Travoprost | 20 | $3,116 |
| Brimonidine Tartrate | 91 | $2,956 |
| Latanoprost | 185 | $2,464 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $666 |
| Dorzolamide Hcl | 13 | $374 |
| Timolol Maleate | 39 | $219 |
| Diclofenac Sodium | 14 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $143 | $41,98181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.